SynBioBeta Speaker
Inja Radman
New Culture
Co-founder & CSO
Originally from beautiful Split, Croatia, Inja received her PhD from The University of Cambridge, MRC LMB, in molecular and synthetic biology and Master’s from ETH Zurich in biophysics and protein structure. After completing postdoctoral research, she worked in analytical consulting in the healthcare and pharmaceutical industries before joining Matt Gibson to co-found New Culture as part of IndieBio, the world’s leading biotech start-up accelerator. New Culture is a pioneer in animal-free casein protein production, enabling the company to produce functional and delicious dairy cheese not dependent on animal agriculture supply chain. At New Culture, Inja leads the company’s R&D, technology, manufacturing and product pipelines.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Inja
This Year
•
-
Biomanufacturing
Mind the Gap: Survival Guides for the Valleys of Death in Biomanufacturing
Industrial biotech faces repeated “valleys of death” between laboratory success and commercial manufacturing, driven by a combination of technological uncertainty, scale-dependent constraints, and (mis)alignment between engineering reality and investment expectations. Promising technologies often fail not because the science is wrong, but because scale-up trajectories are built on insufficient data, optimistic assumptions, and decision-making based on the 1st product specifications from the lab that do not translate to industrial conditions. This panel returns to fundamentals, drawing on real-world experience from piloting, process engineering, and early industrialization to examine where and why scale-up breaks down. Experts will discuss how important the scale-up journey is to align technology performance with investor expectations, support sound business cases, and turn the industrial biotech toolbox into a more robust, scalable, and profitable manufacturing platform.
Purchase Pass
•
-
Biomanufacturing
Mind the Gap: Survival Guides for the Valleys of Death in Biomanufacturing
Industrial biotech faces repeated “valleys of death” between laboratory success and commercial manufacturing, driven by a combination of technological uncertainty, scale-dependent constraints, and (mis)alignment between engineering reality and investment expectations. Promising technologies often fail not because the science is wrong, but because scale-up trajectories are built on insufficient data, optimistic assumptions, and decision-making based on the 1st product specifications from the lab that do not translate to industrial conditions. This panel returns to fundamentals, drawing on real-world experience from piloting, process engineering, and early industrialization to examine where and why scale-up breaks down. Experts will discuss how important the scale-up journey is to align technology performance with investor expectations, support sound business cases, and turn the industrial biotech toolbox into a more robust, scalable, and profitable manufacturing platform.
Purchase Pass
Session lineup still growing
Purchase Pass
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Purchase Pass
Featuring
Speaker Coming Soon
